Table 2.
Univariate and multivariate cox regression analyses of time to early relapse in patients who were relapse at 2 years after resection with curative intent for intrahepatic cholangiocarcinoma (n = 168).
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age, year (≤50 vs. >50) | 1.299 (0.913–1.849) | 0.147 | NA | NA |
| Sex (female vs. male) | 0.884 (0.647–1.208) | 0.440 | NA | NA |
| HBsAg (negative vs. positive) | 0.805 (0.592–1.096) | 0.168 | NA | NA |
| HCV (negative vs. positive) | 0.305 (0.074–1.248) | 0.098 | NA | NA |
| AFP, ng/ml (≤20 vs. >20) | 1.490 (0.910–2.439) | 0.113 | NA | NA |
| Child-Pugh (A vs. B or C) | 1.030 (0.381–2.785) | 0.953 | NA | NA |
| Liver cirrhosis (no vs. yes) | 1.108 (0.794–1.547) | 0.545 | NA | NA |
| Tumor size, cm (≤5 vs. >5) | 1.167 (0.856–1.591) | 0.329 | NA | NA |
| Tumor number (single vs. multiple) | 1.986 (1.409–2.799) | 0.000 | 1.951(1.382–2.755) | 0.000 |
| Lymphonodus node metastasis (no vs. yes) | 1.558 (1.093–2.219) | 0.014 | 1.517(1.061–2.168) | 0.022 |
| Microvascular invasion (no vs. yes) | 1.593 (0.960–2.643) | 0.072 | NA | NA |
| Tumor differentiationa (P vs. M,W) | 1.107 (0.815–1.502) | 0.516 | NA | NA |
| TNM stageb (I+II vs. III+IVA) | 1.336 (0.962–1.856) | 0.084 | NA | NA |
| NLR (low vs. high) | 1.318 (0.968–1.795) | 0.080 | NA | NA |
| PLR (low vs. high) | 1.259 (0.927–1.710) | 0.140 | NA | NA |
| LMR (low vs. high) | 0.812 (0.584–1.128) | 0.214 | NA | NA |
| CA19-9, U/ml (≤89 vs. >89) | 1.478 (1.084–2.016) | 0.013 | 1.495 (1.095–2.039) | 0.011 |
NA, not applicable.
Boldface type indicates significant values.
Analyses were conducted using univariate analysis or multivariate Cox proportional hazards regression.
AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; TNM, tumor-node-metastasis; CI, confidential interval; P, poor differentiation; M, moderated differentiation; W, well-differentiation.
Tumor differentiation was determined according to the “British Society of Gastroenterology guidelines on the management of cholangiocarcinoma”.
TNM stage: American Joint Committee on Cancer 7th edition staging for intrahepatic cholangiocarcinoma.